Latest Operating Expenses News

Promisia Healthcare reported a robust 29% increase in operating revenue for FY26, alongside a new dividend policy tied to operating free cash flow, setting the stage for continued growth in FY27.

KMD Brands delivered steady sales growth and margin improvement in Q3 FY26, driven by Kathmandu and Rip Curl, while launching a business review to explore options for accelerating shareholder value.

PhosCo Ltd reveals a simplified single-stage flotation process for its Gasaat Phosphate Project that promises lower costs and reduced complexity, boosting prospects ahead of its Q3 2026 scoping study update.

ASX Limited projects a significant 18-21% rise in expenses for FY27 driven by technology modernisation and regulatory response, while increasing capital expenditure guidance to up to $200 million.

Ryman Healthcare reported a substantial reduction in net loss for FY26 alongside its first positive free cash flow in over a decade, driven by operational improvements, refinancing, and land divestments.

Infragreen Group Limited (ASX: IFN) forecasts a robust FY26 with underlying EBITDA rising to $22.5m-$25m and underlying NPAT surging over 270%, driven by solid performances in Energybuild and Pure Environmental. The company anticipates continued momentum into FY27, despite some short-term headwinds in Minemet and Merredin Energy.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

EROAD reported flat group revenue of NZD 195.2 million for FY26, driven by strong Australian growth and steady New Zealand performance, offset by a North American decline and a hefty goodwill impairment.

Legacy Minerals has delivered a robust Scoping Study for its Mt Carrington gold-silver-copper project, confirming a high-margin 12-year operation with significant growth potential and manageable capital requirements.

IPD Group signals a strong FY26 with EBITDA guidance up 18% and robust revenue growth, underpinned by acquisition integration and operational efficiencies.

Australian Agricultural Company (ASX:AAC) defies North Queensland floods to deliver a 23% jump in operating profit, driven by strong beef pricing and herd valuation gains.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.